Bavarian Nordic AS (OCSE:BAVA) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:BAVA Bavarian Nordic AS OCSE:BAVA
80 GF Score
Price kr176.60
GF Value kr160.75
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Bavarian Nordic AS Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

OCSE:BAVA
80GF Score
Bavarian Nordic AS OCSE:BAVA
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bavarian Nordic AS (OCSE:BAVA) Overvalued in 2026?

Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued. The current stock price of kr176.60 is trading 9.9% above its estimated GF Value™ of kr160.75. GuruFocus considers Bavarian Nordic AS to be Fairly Valued.

Key valuation signals for OCSE:BAVA:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: kr160.75 vs. price of kr176.60 (9.9% above fair value)
  • GF Score™: 80/100 with 2 warning signs

No single metric tells the full story. See the OCSE:BAVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bavarian Nordic AS Business Description

Address Philip Heymans Alle 3, Hellerup, DNK, 2900
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
80GF Score

Get the complete analysis for OCSE:BAVA

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr176.60
Price
kr160.75
GF Value